<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>Dept of Chemistry</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/9DB853DC-8439-47DB-8DE3-C3ECF85A904D"><gtr:id>9DB853DC-8439-47DB-8DE3-C3ECF85A904D</gtr:id><gtr:firstName>Rita</gtr:firstName><gtr:surname>Tewari</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/3E87577B-3C4D-4452-92E2-B7884FF8E9B8"><gtr:id>3E87577B-3C4D-4452-92E2-B7884FF8E9B8</gtr:id><gtr:firstName>Edward</gtr:firstName><gtr:otherNames>William</gtr:otherNames><gtr:surname>Tate</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/D92AAB20-B522-41B5-A60B-733789AB1995"><gtr:id>D92AAB20-B522-41B5-A60B-733789AB1995</gtr:id><gtr:firstName>Anthony</gtr:firstName><gtr:otherNames>Arthur</gtr:otherNames><gtr:surname>Holder</gtr:surname><gtr:orcidId>0000-0002-8490-6058</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/35BD288D-BD92-4F2F-A782-9EF6DEA273EB"><gtr:id>35BD288D-BD92-4F2F-A782-9EF6DEA273EB</gtr:id><gtr:firstName>Anthony</gtr:firstName><gtr:surname>Wilkinson</gtr:surname><gtr:orcidId>0000-0003-4577-9479</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/C524C63E-0DA7-4161-9769-46974CABC613"><gtr:id>C524C63E-0DA7-4161-9769-46974CABC613</gtr:id><gtr:firstName>Robin</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Leatherbarrow</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0900278"><gtr:id>EB67B45B-A333-468F-9CB6-30470DD8C7F0</gtr:id><gtr:title>N-Myristoyl Transferase as a drug target for anti-malarial therapy</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0900278</gtr:grantReference><gtr:abstractText>There is a need to develop new drugs to treat malaria, which is one of the most important global infectious diseases, afflicting hundreds of millions of people each year. We have identified a way to kill the parasite causing malaria using chemical compounds that stop the action of a parasite enzyme that has an important role in allowing the parasite to grow in the blood stream and in passing from one individual to another through the mosquito. What we now plan to do is to make new compounds that are even more effective at killing the parasite so that they can form the basis of the development of new drugs against malaria. To make such improvements we will both look for completely new chemical compounds that work in the same way, and make small changes in the size and shape of the compounds we already have to improve their ability to stop the enzyme from working. To do this improvement work most effectively we need to know the shape and structure of the enzyme and whether or not the compounds can get into the parasite cell to kill it. By understanding how stopping the action of the enzyme kills the parasite we can use the knowledge to develop better ways of testing these potential therapeutics against the parasite in the test tube and within the blood stream. The goal of the project is therefore to confirm that new and better chemical compounds can be developed that are more effective in stopping the action of this enzyme and therefore in killing the parasite that causes malaria. One or more of these compounds may form the basis of a further programme in collaboration with pharmaceutical industry to develop therapeutic drugs.</gtr:abstractText><gtr:technicalSummary>There is an urgent need for new anti-malarial drugs and for elimination of the disease these must be active against both Plasmodium falciparum and P. vivax, the two most important human malaria parasites. Such drugs should be effective against both the parasite stage responsible for causing disease and against the sexual blood stage that is essential for transmission. We have identified Plasmodium protein:N-myristoyl transferase (NMT) as a suitable target for such drugs and validated it both genetically and chemically. We aim to develop highly effective inhibitors of NMT that are active against the purified enzyme, and will kill the malaria parasite in vitro and in in vivo. Two existing series of inhibitors will be optimised using medicinal chemistry methods and additional leads will be obtained by screening libraries of compounds. Structural studies on the enzyme and inhibitors will inform this process. Active compounds will be screened against P. falciparum asexual blood stages in vitro using a FACS-based assay to identify and select those most active against this parasite. Selected compounds will also be examined for their ability to inhibit gametocytogenesis. We have developed a transgenic rodent malaria parasite, P. berghei that has the P. falciparum NMT gene inserted into the endogenous NMT locus, and this parasite line will be used to screen the efficacy of compounds in vivo against blood stage parasites, including sexual stages. We propose to further validate this model and develop similar parasites transgenic for the P. vivax enzyme so that the efficacy of the inhibitors against this parasite can be evaluated. We will further develop cell biological assays to confirm on-target effects of NMT inhibitors by examining the properties of particular NMT substrates. At the end of the project we will have produced a number of highly active compounds suitable for further drug development in collaboration with Pharma, and provided a clear understanding of the role for NMT in the biology of the malaria parasite.</gtr:technicalSummary><gtr:fund><gtr:end>2014-05-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-06-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1406127</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>750000</gtr:amountPounds><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>MMV Development Portfolio</gtr:description><gtr:end>2017-12-02</gtr:end><gtr:fundingOrg>Medicines for Malaria Venture (MMV)</gtr:fundingOrg><gtr:id>36E53491-1030-432C-A392-FF1438824FF3</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>56000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Doctoral Prize Fellowship (Megan Wright)</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:id>A789922C-30D6-4A18-9C81-259A8B8B9B47</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>70000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EPSRC PhD studentship</gtr:description><gtr:end>2014-10-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:id>69EA12B7-9035-41A2-8B75-47E7F4F35B72</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>56017</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Doctoral Prize Fellowship (Mark Rackham)</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:id>B321E32C-92FE-4B3E-83D3-7666688517E5</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>A novel series of inhibitors of the enzyme N-myristoyltransferase, with therapeutic applications in multiple diseases.</gtr:description><gtr:id>B2A77CF8-2F4E-4BAA-8FC3-405D3B925233</gtr:id><gtr:impact>Additional funding and collaborations, as noted elsewhere.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>WO2013083991A1</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Novel compounds and their use in therapy</gtr:title><gtr:yearProtectionGranted>2015</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>This invention relates to compounds for formula (I), (IIA), (IIB), (IIC), (IID), (IIE), (III) and (IV), which are N-myristoyl transferase inhibitors, and to uses of such compounds as medicaments, in particular in the treatment of a disease or disorder in which inhibition of N-myristoyl transferase provides a therapeutic or prophylactic effect. Such diseases include microbial infections, including viral and fungal infections, and hyperproliferative disorders, neurological diseases/disorders, ischemia, osteoporosis and diabetes. Certain compounds of the invention find particular use in the treatment of protozoan infections, for example malaria, leishmaniasis and sleeping sickness.</gtr:description><gtr:id>148C6036-A3FA-48A3-BC4B-719E309AEC4B</gtr:id><gtr:impact>Ongoing...</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:patentId>US20110245460</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Novel compounds and their use in therapy</gtr:title><gtr:yearProtectionGranted>2011</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7322F212-84C1-4DB7-9BBA-2D033923C1BA"><gtr:id>7322F212-84C1-4DB7-9BBA-2D033923C1BA</gtr:id><gtr:title>A unique protein phosphatase with kelch-like domains (PPKL) in Plasmodium modulates ookinete differentiation, motility and invasion.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/068ca74a42ae3f77d1c8f35065f0a4fd"><gtr:id>068ca74a42ae3f77d1c8f35065f0a4fd</gtr:id><gtr:otherNames>Guttery DS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3BB0D6A7-76C8-474F-90BC-37FCB6E880F8"><gtr:id>3BB0D6A7-76C8-474F-90BC-37FCB6E880F8</gtr:id><gtr:title>Discovery of Plasmodium vivax N-myristoyltransferase inhibitors: screening, synthesis, and structural characterization of their binding mode.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ad06962ecc8a6d299082b428da241483"><gtr:id>ad06962ecc8a6d299082b428da241483</gtr:id><gtr:otherNames>Goncalves V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7052E7F0-0D02-4D7A-9FA6-B3F790240AF9"><gtr:id>7052E7F0-0D02-4D7A-9FA6-B3F790240AF9</gtr:id><gtr:title>Unique apicomplexan IMC sub-compartment proteins are early markers for apical polarity in the malaria parasite.</gtr:title><gtr:parentPublicationTitle>Biology open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a0629add4e897b75207dab5a0455d222"><gtr:id>a0629add4e897b75207dab5a0455d222</gtr:id><gtr:otherNames>Poulin B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2046-6390</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/24175C6E-93EA-49A9-B054-AA885322E69A"><gtr:id>24175C6E-93EA-49A9-B054-AA885322E69A</gtr:id><gtr:title>Commit and Transmit: Molecular Players in Plasmodium Sexual Development and Zygote Differentiation.</gtr:title><gtr:parentPublicationTitle>Trends in parasitology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/068ca74a42ae3f77d1c8f35065f0a4fd"><gtr:id>068ca74a42ae3f77d1c8f35065f0a4fd</gtr:id><gtr:otherNames>Guttery DS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1471-4922</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B69119A7-9A8F-4820-BF9D-81346828B138"><gtr:id>B69119A7-9A8F-4820-BF9D-81346828B138</gtr:id><gtr:title>An ancient protein phosphatase, SHLP1, is critical to microneme development in Plasmodium ookinetes and parasite transmission.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/23dfa25c0defe9c651c5f776319d0e7c"><gtr:id>23dfa25c0defe9c651c5f776319d0e7c</gtr:id><gtr:otherNames>Patzewitz EM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5B7407EE-E69E-48B1-B77A-886C556D56FA"><gtr:id>5B7407EE-E69E-48B1-B77A-886C556D56FA</gtr:id><gtr:title>SAS6-like protein in Plasmodium indicates that conoid-associated apical complex proteins persist in invasive stages within the mosquito vector.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9a150780c99a733dae411dead5fe6e9a"><gtr:id>9a150780c99a733dae411dead5fe6e9a</gtr:id><gtr:otherNames>Wall RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E77A51AC-0501-4F0D-9DFE-CF6EA418085E"><gtr:id>E77A51AC-0501-4F0D-9DFE-CF6EA418085E</gtr:id><gtr:title>Structure-based design of potent and selective Leishmania N-myristoyltransferase inhibitors.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/66c8acb38925d78f8f817daba0273308"><gtr:id>66c8acb38925d78f8f817daba0273308</gtr:id><gtr:otherNames>Hutton JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/62ED2ACC-5F2C-49DA-84AF-13F46819673B"><gtr:id>62ED2ACC-5F2C-49DA-84AF-13F46819673B</gtr:id><gtr:title>Global profiling of co- and post-translationally N-myristoylated proteomes in human cells.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/793e5a3fdbbbfc8d5c6eb2675c2677cf"><gtr:id>793e5a3fdbbbfc8d5c6eb2675c2677cf</gtr:id><gtr:otherNames>Thinon E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DAD5A81B-51B5-498C-86AD-FFA2F1C057D2"><gtr:id>DAD5A81B-51B5-498C-86AD-FFA2F1C057D2</gtr:id><gtr:title>Plasmodium P-Type Cyclin CYC3 Modulates Endomitotic Growth during Oocyst Development in Mosquitoes.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d1ddc315422b7202098bd167ccc0fd88"><gtr:id>d1ddc315422b7202098bd167ccc0fd88</gtr:id><gtr:otherNames>Roques M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FAF140CA-DB5B-4A01-BAE5-89AADBF9FAF9"><gtr:id>FAF140CA-DB5B-4A01-BAE5-89AADBF9FAF9</gtr:id><gtr:title>Discovery of Plasmodium vivax N-myristoyltransferase inhibitors: screening, synthesis, and structural characterization of their binding mode.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ad06962ecc8a6d299082b428da241483"><gtr:id>ad06962ecc8a6d299082b428da241483</gtr:id><gtr:otherNames>Goncalves V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0F783DE0-AF46-40BA-AAC4-25042C8854A2"><gtr:id>0F783DE0-AF46-40BA-AAC4-25042C8854A2</gtr:id><gtr:title>Design and synthesis of inhibitors of Plasmodium falciparum N-myristoyltransferase, a promising target for antimalarial drug discovery.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/26b47713a984b0d968164e2c55d612c7"><gtr:id>26b47713a984b0d968164e2c55d612c7</gtr:id><gtr:otherNames>Yu Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F07A51EF-37D0-4682-A7D9-86089A7F778B"><gtr:id>F07A51EF-37D0-4682-A7D9-86089A7F778B</gtr:id><gtr:title>N-myristoyltransferase from Leishmania donovani: structural and functional characterisation of a potential drug target for visceral leishmaniasis.</gtr:title><gtr:parentPublicationTitle>Journal of molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/646af72e292bf028b604a94eebd4119f"><gtr:id>646af72e292bf028b604a94eebd4119f</gtr:id><gtr:otherNames>Brannigan JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-2836</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/64E1E187-CC90-43D9-A16B-8FC7FF5E1E0C"><gtr:id>64E1E187-CC90-43D9-A16B-8FC7FF5E1E0C</gtr:id><gtr:title>Discovery of pyridyl-based inhibitors of Plasmodium falciparum N-myristoyltransferase.</gtr:title><gtr:parentPublicationTitle>MedChemComm</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/26b47713a984b0d968164e2c55d612c7"><gtr:id>26b47713a984b0d968164e2c55d612c7</gtr:id><gtr:otherNames>Yu Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2040-2503</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0CF0AA8C-9623-4323-931E-9C74A5DDB3CE"><gtr:id>0CF0AA8C-9623-4323-931E-9C74A5DDB3CE</gtr:id><gtr:title>Genome-wide functional analysis of Plasmodium protein phosphatases reveals key regulators of parasite development and differentiation.</gtr:title><gtr:parentPublicationTitle>Cell host &amp; microbe</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/068ca74a42ae3f77d1c8f35065f0a4fd"><gtr:id>068ca74a42ae3f77d1c8f35065f0a4fd</gtr:id><gtr:otherNames>Guttery DS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1931-3128</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E31FCBA4-2342-4889-AD12-BA0808B55A43"><gtr:id>E31FCBA4-2342-4889-AD12-BA0808B55A43</gtr:id><gtr:title>A putative homologue of CDC20/CDH1 in the malaria parasite is essential for male gamete development.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/068ca74a42ae3f77d1c8f35065f0a4fd"><gtr:id>068ca74a42ae3f77d1c8f35065f0a4fd</gtr:id><gtr:otherNames>Guttery DS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/486FBA7E-B1C3-4916-BA6E-95BA69F5DE35"><gtr:id>486FBA7E-B1C3-4916-BA6E-95BA69F5DE35</gtr:id><gtr:title>Discovery of novel and ligand-efficient inhibitors of Plasmodium falciparum and Plasmodium vivax N-myristoyltransferase.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/279bada1cad6b512f5336dfb4b078606"><gtr:id>279bada1cad6b512f5336dfb4b078606</gtr:id><gtr:otherNames>Rackham MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/47DA2457-2ED5-46E4-B5EF-0896B02A4BEB"><gtr:id>47DA2457-2ED5-46E4-B5EF-0896B02A4BEB</gtr:id><gtr:title>A fluorescence-based assay for N-myristoyltransferase activity.</gtr:title><gtr:parentPublicationTitle>Analytical biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ad06962ecc8a6d299082b428da241483"><gtr:id>ad06962ecc8a6d299082b428da241483</gtr:id><gtr:otherNames>Goncalves V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0003-2697</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DB4C7790-7FDE-4397-AC60-F29E7C4B0AB7"><gtr:id>DB4C7790-7FDE-4397-AC60-F29E7C4B0AB7</gtr:id><gtr:title>Selective inhibitors of protozoan protein N-myristoyltransferases as starting points for tropical disease medicinal chemistry programs.</gtr:title><gtr:parentPublicationTitle>PLoS neglected tropical diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e41c5f5775e9a24eb6211733493b23ef"><gtr:id>e41c5f5775e9a24eb6211733493b23ef</gtr:id><gtr:otherNames>Bell AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1935-2727</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3EE4E3AB-10A1-4E1F-A4AB-2A9F3A292E9D"><gtr:id>3EE4E3AB-10A1-4E1F-A4AB-2A9F3A292E9D</gtr:id><gtr:title>N-Myristoyltransferase as a potential drug target in malaria and leishmaniasis.</gtr:title><gtr:parentPublicationTitle>Parasitology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8634e274b052728aee7600cfe61ac7c9"><gtr:id>8634e274b052728aee7600cfe61ac7c9</gtr:id><gtr:otherNames>Tate EW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0031-1820</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5C4DDE9E-AED7-47D6-BDEA-5D3E641B5C73"><gtr:id>5C4DDE9E-AED7-47D6-BDEA-5D3E641B5C73</gtr:id><gtr:title>Structure-guided optimization of quinoline inhibitors of Plasmodium N-myristoyltransferase</gtr:title><gtr:parentPublicationTitle>Med. Chem. Commun.</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ad06962ecc8a6d299082b428da241483"><gtr:id>ad06962ecc8a6d299082b428da241483</gtr:id><gtr:otherNames>Goncalves V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5E96E50B-E430-48BA-BC37-B251CE3BA165"><gtr:id>5E96E50B-E430-48BA-BC37-B251CE3BA165</gtr:id><gtr:title>Sexual development in Plasmodium: lessons from functional analyses.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/068ca74a42ae3f77d1c8f35065f0a4fd"><gtr:id>068ca74a42ae3f77d1c8f35065f0a4fd</gtr:id><gtr:otherNames>Guttery DS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/25A58D49-77E0-4998-9A53-EA0851466B87"><gtr:id>25A58D49-77E0-4998-9A53-EA0851466B87</gtr:id><gtr:title>Validation of N-myristoyltransferase as an antimalarial drug target using an integrated chemical biology approach.</gtr:title><gtr:parentPublicationTitle>Nature chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/53824c30faf115b3a214f0a9105e463e"><gtr:id>53824c30faf115b3a214f0a9105e463e</gtr:id><gtr:otherNames>Wright MH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1755-4330</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5819173E-F099-4750-9180-89BB53C88899"><gtr:id>5819173E-F099-4750-9180-89BB53C88899</gtr:id><gtr:title>A fluorescence-based assay for N-myristoyltransferase activity.</gtr:title><gtr:parentPublicationTitle>Analytical biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ad06962ecc8a6d299082b428da241483"><gtr:id>ad06962ecc8a6d299082b428da241483</gtr:id><gtr:otherNames>Goncalves V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0003-2697</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/49D34B8D-8ADD-4FF1-91CC-6FF6CE2DD2BA"><gtr:id>49D34B8D-8ADD-4FF1-91CC-6FF6CE2DD2BA</gtr:id><gtr:title>Development of a transgenic Plasmodium berghei line (Pb pfpkg) expressing the P. falciparum cGMP-dependent protein kinase, a novel antimalarial drug target.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e74fa93145fbbe3f0f5dd4cb0ad89bb5"><gtr:id>e74fa93145fbbe3f0f5dd4cb0ad89bb5</gtr:id><gtr:otherNames>Tewari R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/53AB1764-2DFF-44CA-B5D0-CE2407F92A3B"><gtr:id>53AB1764-2DFF-44CA-B5D0-CE2407F92A3B</gtr:id><gtr:title>Discovery of novel and ligand-efficient inhibitors of Plasmodium falciparum and Plasmodium vivax N-myristoyltransferase.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/279bada1cad6b512f5336dfb4b078606"><gtr:id>279bada1cad6b512f5336dfb4b078606</gtr:id><gtr:otherNames>Rackham MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C58D4E71-B9C9-47F9-B168-2C883034D0D6"><gtr:id>C58D4E71-B9C9-47F9-B168-2C883034D0D6</gtr:id><gtr:title>Selective inhibitors of protozoan protein N-myristoyltransferases as starting points for tropical disease medicinal chemistry programs.</gtr:title><gtr:parentPublicationTitle>PLoS neglected tropical diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e41c5f5775e9a24eb6211733493b23ef"><gtr:id>e41c5f5775e9a24eb6211733493b23ef</gtr:id><gtr:otherNames>Bell AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1935-2727</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2949F2AD-AD8B-4922-92BE-14E2C5FB1AF2"><gtr:id>2949F2AD-AD8B-4922-92BE-14E2C5FB1AF2</gtr:id><gtr:title>Peptidomimetic inhibitors of N-myristoyltransferase from human malaria and leishmaniasis parasites.</gtr:title><gtr:parentPublicationTitle>Organic &amp; biomolecular chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e2ffb4b4ed63e0a3de3bb157bfd0845d"><gtr:id>e2ffb4b4ed63e0a3de3bb157bfd0845d</gtr:id><gtr:otherNames>Olaleye TO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1477-0520</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F418A151-EFFB-40B5-B754-C3499664981B"><gtr:id>F418A151-EFFB-40B5-B754-C3499664981B</gtr:id><gtr:title>Design and synthesis of inhibitors of Plasmodium falciparum N-myristoyltransferase, a promising target for antimalarial drug discovery.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/26b47713a984b0d968164e2c55d612c7"><gtr:id>26b47713a984b0d968164e2c55d612c7</gtr:id><gtr:otherNames>Yu Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8C49C1E9-0458-443B-B4B1-76353E2CF503"><gtr:id>8C49C1E9-0458-443B-B4B1-76353E2CF503</gtr:id><gtr:title>The Plasmodium berghei Ca(2+)/H(+) exchanger, PbCAX, is essential for tolerance to environmental Ca(2+) during sexual development.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/068ca74a42ae3f77d1c8f35065f0a4fd"><gtr:id>068ca74a42ae3f77d1c8f35065f0a4fd</gtr:id><gtr:otherNames>Guttery DS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EC1B1654-639C-438C-BF8F-C5AC40B391BB"><gtr:id>EC1B1654-639C-438C-BF8F-C5AC40B391BB</gtr:id><gtr:title>Design and synthesis of high affinity inhibitors of Plasmodium falciparum and Plasmodium vivax N-myristoyltransferases directed by ligand efficiency dependent lipophilicity (LELP).</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/279bada1cad6b512f5336dfb4b078606"><gtr:id>279bada1cad6b512f5336dfb4b078606</gtr:id><gtr:otherNames>Rackham MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A18139AB-2308-417D-8213-E1E2E7A5C99C"><gtr:id>A18139AB-2308-417D-8213-E1E2E7A5C99C</gtr:id><gtr:title>The repeat region of the circumsporozoite protein is critical for sporozoite formation and maturation in Plasmodium.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8de049b7be8c1d758e7faf19454dd051"><gtr:id>8de049b7be8c1d758e7faf19454dd051</gtr:id><gtr:otherNames>Ferguson DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0900278</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>